<DOC>
	<DOCNO>NCT01061099</DOCNO>
	<brief_summary>This study evaluate safety effectiveness repeat Mesenchymal Stromal Cells ( MSC ) infusion patient Type II III osteogenesis imperfecta ( OI ) . Participants receive MSC infusion approximately every 4 month complete total 6 infusion 20 month . Participants follow 4 month post last MSC infusion .</brief_summary>
	<brief_title>Repeated Infusions Mesenchymal Stromal Cells Children With Osteogenesis Imperfecta</brief_title>
	<detailed_description>This pilot study evaluate safety efficacy repeat MSC infusion subject OI . This study evaluate subject two separate stratum . Stratum A include subject diagnosis Type II Type III osteogenesis imperfecta previously undergone bone marrow transplant . Stratum A may use previously harvest cryopreserved bone marrow mononuclear cell original BMT donor freshly harvest cryopreserved bone marrow mononuclear cell obtain haploidentical healthy parent sibling . Stratum B include subject Type II III osteogenesis imperfecta undergone bone marrow transplant . Stratum B receive freshly harvest cryopreserved bone marrow mononuclear cell haploidentical healthy parent sibling . Participants receive MSC infusion approximately every 4 month complete total 6 infusion 20 month . Participants follow 12 month post last MSC infusion .</detailed_description>
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<criteria>Subjects less equal 19 year age time enrollment Children diagnosis severe Type II III osteogenesis imperfecta Parent sibling great equal 18 year age , donor willing already undergone HLA typing , willing able provide bone marrow BMT great 5 year ago Stratum A Dependent supplemental oxygen Concurrent Infection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Type II Type III Osteogenesis imperfecta</keyword>
	<keyword>OI</keyword>
	<keyword>Mesenchymal Stromal Cells</keyword>
	<keyword>MSC</keyword>
</DOC>